当前位置：
X-MOL 学术
›
Alzheimers Dement.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab
Alzheimer's & Dementia ( IF 14.0 ) Pub Date : 2024-04-03 , DOI: 10.1002/alz.13755 Tianle Chen 1 , John O'Gorman 1 , Carmen Castrillo‐Viguera 1 , Rajasimhan Rajagovindan 1 , Gioacchino G. Curiale 1 , Ying Tian 1 , Dakshaben Patel 2 , Philipp von Rosenstiel 1 , Christian von Hehn 1 , Stephen Salloway 3 , Christoph Hock 4 , Roger M. Nitsch 4 , Samantha Budd Haeberlein 1 , Alfred Sandrock 1 , Priya Singhal 1
Alzheimer's & Dementia ( IF 14.0 ) Pub Date : 2024-04-03 , DOI: 10.1002/alz.13755 Tianle Chen 1 , John O'Gorman 1 , Carmen Castrillo‐Viguera 1 , Rajasimhan Rajagovindan 1 , Gioacchino G. Curiale 1 , Ying Tian 1 , Dakshaben Patel 2 , Philipp von Rosenstiel 1 , Christian von Hehn 1 , Stephen Salloway 3 , Christoph Hock 4 , Roger M. Nitsch 4 , Samantha Budd Haeberlein 1 , Alfred Sandrock 1 , Priya Singhal 1
Affiliation
Aducanumab selectively targets aggregated forms of amyloid beta (Aβ), a neuropathological hallmark of Alzheimer's disease (AD).
中文翻译：
PRIME 长期扩展的结果：aducanumab 的随机 1b 期试验
Aducanumab 选择性地靶向聚集形式的β淀粉样蛋白 (Aβ)，这是阿尔茨海默病 (AD) 的神经病理学标志。
更新日期：2024-04-03
中文翻译：
PRIME 长期扩展的结果：aducanumab 的随机 1b 期试验
Aducanumab 选择性地靶向聚集形式的β淀粉样蛋白 (Aβ)，这是阿尔茨海默病 (AD) 的神经病理学标志。
京公网安备 11010802027423号